In the long human struggle against cancer's most stubborn forms, a small injection has offered something rare — genuine surprise. Researchers in London have reported that amivantamab, a bispecific antibody already approved for certain lung cancers, shrank tumors in nearly half of patients whose head and neck cancers had resisted every standard treatment, with fifteen individuals achieving complete remission. Presented to the American Society of Clinical Oncology, the findings arrive as a quiet but significant turning point for a population that had, in the most practical sense, run out of road
thestar.com.my
· May 31, 2026
· health
· 3 min de leitura
High
Apuração: Verificado
Cancer injection eradicates tumours in treatment-resistant cases
Patients with treatment-resistant head and neck cancer experienced significant quality-of-life improvements, including reduced pain, swelling, and elimination of severe chemotherapy side effects.
◉
Health & Medicine
8046 artigos relacionados
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 100% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% correspondência
Cobertura Relacionada
Google News · Aug 19
Welsh Teen's Ovarian Cancer Diagnosis Triggers Sudden Menopause
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Viés e Enquadramento
⚖
Article presents promising cancer treatment results with optimistic framing and expert endorsement, but lacks critical perspective on limitations, side effects, and commercial interests.
Bias Direction
center-right
Confidence
MED
Positive medical breakthrough narrative emphasizing clinical success and patient testimonials, with prominent expert validation and minimal counterbalance on uncertainties or commercial context.
unprecedentedly strong responses
eradicated entire tumours
very striking
potential to benefit many thousands
life-impacting side effects
extremely limited
Cost and accessibility concerns for patients in different healthcare systems
Long-term follow-up data and durability of responses
Comparison with competing treatments in development
Potential adverse effects beyond chemotherapy comparison
Independent analysis not affiliated with trial sponsors
Patient advocacy group perspectives on realistic expectations
Regulatory pathway and timeline to market availability
Johnson & Johnson's commercial interests and pricing strategy
Impacto Geopolítico
🌎
New injectable cancer treatment shows breakthrough efficacy in treatment-resistant cases, with potential global health implications and pharmaceutical market shifts favoring advanced biotechnology.
Escalation Risk
low
Confidence
HIGH
United Kingdom
United States
European Union
Global healthcare systems
11 countries participating in trial
Johnson & Johnson strengthens market position in oncology; UK/EU research institutions gain prestige; potential shift in cancer treatment paradigm from chemotherapy-dependent to targeted immunotherapy approaches; developing nations may face access/affordability challenges for advanced treatments.
Similar to the introduction of monoclonal antibodies (Herceptin, 1998) which revolutionized cancer treatment and reshaped pharmaceutical competition, establishing new standards of care and market dominance.
Lente Econômica
📈
Amivantamab injection shows strong efficacy in treatment-resistant head and neck cancer, potentially expanding addressable market for oncology therapeutics and creating new revenue streams for Johnson & Johnson.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and Biotechnology
Healthcare Services and Hospitals
Medical Devices and Diagnostics
Health Insurance
Patients gain access to effective treatment option with fewer side effects and easier administration (injection vs. intravenous drips), potentially reducing healthcare burden and improving quality of life for treatment-resistant cancer patients and their families.
Regulatory bodies (FDA, EMA) may accelerate approval pathways; healthcare systems must evaluate reimbursement and budget allocation for new oncology treatments; potential for expanded clinical trial requirements; pricing negotiations between governments and pharmaceutical companies likely to intensify.